Cerebrospinal fluid plasminogen activator inhibitor-1 in patients with neurological disease
Cerebrospinal fluid plasminogen activator inhibitor-1 in patients with neurological disease
复制标题
DOI：
10.1136/jcp.50.2.157
复制
发表时间：
1997-02-01
影响因子：
3.4
通讯作者：
Vaheri, A
中科院分区：
文献类型：
--
作者：
Akenami, FOT;Koskiniemi, M;Vaheri, A
目的--研究神经系统疾病患者脑脊液（CSF）中纤溶酶原激活物抑制物-1（派-1）的浓度。方法--用ELISA法测定51例神经系统疾病患者和20例正常对照者CSF中派-1的浓度。患者组包括3例病毒性脑膜炎，20例脑炎，9例急性淋巴细胞白血病（n = 7）和髓系白血病（n = 2）（中枢神经系统受累），和19例多发性sclerosis.Results-Raised派-1浓度观察白血病，脑炎和多发性硬化症患者。脑膜炎患者的派-1平均浓度与对照组相比无差异。最高的平均（SEM）派-1浓度被发现在白血病患者（1.28（0.36）ng/ml），其次是脑炎患者（1.19（0.20）ng/ml）。这些值远高于病毒性脑膜炎患者。在以前的报告中，脑脊液组织型纤溶酶原激活剂（tPA）的活动，检测到多发性硬化症，白血病和脑炎患者，平均活动降序。派-1浓度在相同的患者是相反的，他们相应的tPA活动，在那些与白血病和脑炎，比多发性硬化症患者更高。无论是患者还是对照组，CSF派-1浓度与年龄之间均无相关性。同样地，CSF派-1浓度和尿激酶型纤溶酶原激活物（uPA）之间也没有相关性。结论--CSF派-1浓度升高可作为神经系统疾病的非特异性标志物。派-1可能在调节CSF中tPA和uPA的功能中起重要作用。
Aim--To study cerebrospinal fluid (CSF) concentrations of plasminogen activator inhibitor type-1 (PAI-1) in patients with neurological disease.Methods-CSF PAI-1 concentrations were measured in 51 patients with neurological disease and 20 reference subjects using an ELISA. The patient group comprised three patients with viral meningitis, 20 with encephalitis, nine with acute lymphoblastic (n = 7) and myeloid (n = 2) leukaemia (with central nervous system involvement), and 19 with multiple sclerosis.Results-Raised PAI-1 concentrations were observed in patients with leukaemia, encephalitis and multiple sclerosis. There was no difference in the mean concentrations of PAI-1 in patients with meningitis when compared with the reference subjects. The highest mean (SEM) PAI-1 concentration was found in patients with leukaemia (1.28 (0.36) ng/ml), and the next highest in those with encephalitis (1.19 (0.20) ng/ml). These values were much higher than those in patients with viral meningitis. In a previous report, raised CSF tissue-type plasminogen activator (tPA) activities were detected in patients with multiple sclerosis, leukaemia and encephalitis, with mean activities in decreasing order. PAI-1 concentrations in the same patients were the reverse of their corresponding tPA activities, being higher in those with leukaemia and encephalitis, than in patients with multiple sclerosis. There was no association between CSF PAI-1 concentrations and age in either patients or controls. Similarly, there was no association between CSF PAI-1 concentrations and urokinase-type plasminogen activator (uPA).Conclusions--Raised CSF PAI-1 concentrations may be used as a non-specific marker of neurological disease. Moreover, PAI-1 may play an important role in regulating the functions of tPA, and probably uPA, in CSF.